About Leyden Labs

We all harbor and spread respiratory viruses. Moreover, we are often in the dark when initial infection and transmission occurs. This is something we have seen in recent years: for influenza, RSV and coronaviruses, we have a very real problem of severe disease and asymptomatic spread.

This is why at Leyden Labs, we want to stop infections early on, at the very gate through which they enter. In the case of respiratory viruses: the nasal mucosa. We have developed an Mucosal Immunity technology platform, through which we can engineer molecules that are effective in the nasal mucosa. 

Our company is developing nasal sprays containing antibodies that target respiratory viruses in the nasal mucosa. These sprays aim to:

• Fight the initial infection at the gate: which can prevent onward transmission.• Protect broadly against existing and new viruses.
• Provide universal protection, regardless of an individual’s immune history or comorbidities.

With our products, we fight viruses where they fight us, to prepare us for future endemic and pandemic threats. We have a pipeline of clinical and pre-clinical candidates for influenza and corona viruses.

The company’s founders are biotechnology veterans who founded and built vaccine pioneer Crucell. Leyden Labs has raised $200M from investors including GV, Casdin Capital, F-Prime, SoftBank, and Byers Capital/Brook Byers.